How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development Blog How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development Quantitative Systems Pharmacology (QSP) helps address key challenges in Alzheimer’s disease drug development, including tau…CertaraFebruary 2, 2026
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy Webinar Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy CertaraJanuary 22, 2026
Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data On-Demand Webinar Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…CertaraJanuary 13, 2026
New Approach Methodologies (NAMs): By the numbers Guide New Approach Methodologies (NAMs): By the numbers We outline today’s animal-use landscape, the rise of NAMs, & how the Non-Animal Navigator supports…CertaraDecember 10, 2025
New Approach Methodologies: Redefining Animal Testing Alternatives PodcastPress Coverage New Approach Methodologies: Redefining Animal Testing Alternatives Explore how New Approach Methodologies (NAMs) and advanced in silico and in vitro tools are…CertaraDecember 10, 2025
A Guide to the FDA Announcement to Phase Out Animal Testing for Drugs Guide A Guide to the FDA Announcement to Phase Out Animal Testing for Drugs The FDA is phasing out animal testing of new drugs. Learn how Certara’s Non-Animal Navigator™…CertaraNovember 17, 2025
Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs Announcement Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs Certara’s new survey findings show that 50% of Americans are unaware of FDA and NIH…CertaraNovember 12, 2025
Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk Publication Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk Immunogenicity poses a significant challenge in biotherapeutics development due to the formation of anti-drug antibodies…Danielle PillsburyNovember 7, 2025
In silico Safety and Toxicology assessment: ToxStudio® On-Demand Webinar In silico Safety and Toxicology assessment: ToxStudio® Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…CertaraOctober 30, 2025
Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research Press Coverage Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research The article, "Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research," explores a…Danielle PillsburySeptember 10, 2025